S100a9 is mainly produced by innate immune cells, which possess intrinsic amyloidogenic properties and the ability to modulate Aβ aggregation and can serve as a prospective therapeutic target for AD (Wang et al., 2014). The gene discussed is S100A9; the disease is Alzheimer disease.